醋酸戈舍瑞林缓释植入剂治疗前列腺癌的疗效及对患者炎症因子水平的影响

Efficacy of goseraline acetate sustained-release implant in the treatment of prostate cancer and its effect on cellular inflammatory response factors

目的探讨醋酸戈舍瑞林缓释植入剂治疗前列腺癌的疗效及对患者炎症因子水平的影响。方法选取2021年1—12月盐城市第一人民医院收治的100例前列腺癌患者作为研究对象,根据红蓝球抽签结果分为观察组与对照组,每组50例。对照组采用比卡鲁胺治疗,观察组在对照组基础上联合醋酸戈舍瑞林缓释植入剂治疗,比较两组临床疗效、炎症因子水平[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)]、免疫组化标志物[α-甲酰基辅酶A消旋酶(AMACR)、前列腺特异抗原(PSA)]及不良反应发生率。结果观察组治疗总有效率为96.00%,高于对照组的74.00%,差异有统计学意义(P<0.05)。治疗后,两组TNF-α、IL-6水平均低于治疗前,IL-10水平高于治疗前,且观察组TNF-α、IL-6水平均低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05)。治疗后,两组AMACR、PSA水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论醋酸戈舍瑞林缓释植入剂联合比卡鲁胺片治疗前列腺癌疗效显著,可有效降低患者炎症水平,安全性较高,值得临床推广应用。

Objective To investigate the efficacy of goserrelin acetate sustained-release implant in the treatment of prostate cancer and its effect cellular inflammatory response factors.Methods 100 patients with prostate cancer treated in Yancheng First People's Hospital from January to December 2021 were selected as the research subjects,and they were divided into the observation group and the control group according to the re-sults of red and blue ball lottery,with 50 cases in each group.The control group was treated with bicalutamide,and the observation group was treated with goserrelin acetate sustained-release implant on the basis of the control group,the clinical efficacy,inflammatory factor levels(tumor necrosis factor-α[TNF-α],interleukin-6[IL-6],interleukin-10[IL-10]),immunohistochemical markers(alpha-methylacyl-CoA racemase[AMACR],prostate-specific antigen[PSA])and the incidence of adverse reactions were compared between the two groups.Results The total effective rate in the obser-vation group was 96.00%,which was higher than 74.00%in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of TNF-αand IL-6 of the two groups were lower than those before treatment,and the levels of IL-10 were higher than that before treat-ment,and the levels of TNF-αand IL-6 in the observation group were lower than those in the control group,and the level of IL-10 was higher than that in the control group,and the differences were statistically significant(P<0.05).After treatment,AMACR and PSA of the two groups were lower than before treatment,and observation group was lower than control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Gos-errelin acetate sustained-release implant combined with bicalutamide tablet is effective in the treatment of prostate cancer,can effectively reduce the level of inflammation in patients,and is safe,which is worthy of clinical promotion and application.